Myrtelle's Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes To date, 3 patients received
While the Landsman family is optimistic that the gene therapy will help their two sons, they also hope it will help families not receive same dire prognosis.